Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Free Cash Flow (2019 - 2025)

AVITA Medical (RCEL) has disclosed Free Cash Flow for 5 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 62.64% year-over-year to -$6.3 million, compared with a TTM value of -$32.2 million through Dec 2025, up 44.59%, and an annual FY2025 reading of -$32.2 million, up 44.59% over the prior year.
  • Free Cash Flow was -$6.3 million for Q4 2025 at AVITA Medical, down from -$4.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.9 million in Q3 2022 and bottomed at -$22.0 million in Q1 2024.
  • Average Free Cash Flow over 4 years is -$9.3 million, with a median of -$9.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow plummeted 292.94% in 2023, then soared 62.64% in 2025.
  • Year by year, Free Cash Flow stood at -$3.1 million in 2022, then tumbled by 292.94% to -$12.1 million in 2023, then plummeted by 38.87% to -$16.8 million in 2024, then surged by 62.64% to -$6.3 million in 2025.
  • Business Quant data shows Free Cash Flow for RCEL at -$6.3 million in Q4 2025, -$4.6 million in Q3 2025, and -$10.8 million in Q2 2025.